Christie NHS Foundation Trust


Hospital

Location:
Manchester, United Kingdom


Publications in cooperation with FAU scientists


Barnes, P.W., Williamson, C.E., Lucas, R.M., Robinson, S.A., Madronich, S., Paul, N.D.,... Zepp, R.G. (2019). Ozone depletion, ultraviolet radiation, climate change and prospects for a sustainable future. Nature Sustainability. https://dx.doi.org/10.1038/s41893-019-0314-2
Lamarca, A., Ronot, M., Moall, S., Crona, J., Opalinska, M., Lopez, C.,... Dromain, C. (2019). Tumour Growth Rate (TGR) in Neuroendocrine Tumours (NETs): Changes Following Systemic Treatment; the GREPONET-2 Study. In NEUROENDOCRINOLOGY (pp. 137-137). BASEL: KARGER.
Lamarca, A., Crona, J., Ronot, M., Opalinska, M., Lopez Lopez, C., Pezzutti, D.,... Dromain, C. (2019). Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients’ Outcome in Neuroendocrine Tumors (NET)—The GREPONET Study. Oncologist. https://dx.doi.org/10.1634/theoncologist.2018-0672
Crona, J., Crona, J., Lamarca, A., Ronot, M., Opalinska, M., Lopez Lopez, C.,... Dromain, C. (2018). Pre-Treatment Tumor Growth Rate (TGR0) in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs) Treated with Systemic Therapies: Subgroup Analysis of the GREPONET Study. (pp. 171-171).
Lamarca, A., Crona, J., Ronot, M., Opalinska, M., Lopez Lopez, C., Pezzutti, D.,... Dromain, C. (2018). Value of Tumor Growth Rate (TGR) as an Early Predictor of Patients' Outcome in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs): The GREPONET Study. (pp. 178-178).
Ferreri, A.J.M., Cwynarski, K., Pulczynski, E., Fox, C.P., Schorb, E., La Rosee, P.,... Illerhaus, G. (2017). Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal L. Lancet Haematology, 4(11), e510-e523. https://dx.doi.org/10.1016/S2352-3026(17)30174-6
Ferreri, A.J.M., Cwynarski, K., Pulczynski, E., Ponzoni, M., Deckert, M., Politi, L.S.,... Illerhaus, G. (2016). Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematology, 3(5), e217-27. https://dx.doi.org/10.1016/S2352-3026(16)00036-3
Marx, A., Stroebel, P., Badve, S.S., Chalabreysse, L., Chan, J.K.C., Chen, G.,... Travis, W.D. (2014). ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting. Journal of Thoracic Oncology, 9(5), 596-611. https://dx.doi.org/10.1097/JTO.0000000000000154

Last updated on 2017-16-02 at 08:41